Loading
Fetching the latest research
Paper source
Selective killing of cancer cells with a small molecule targeting stress response to ROS · 10.1038/nature10167
This rigor review was examined and confirmed by Αlpha¹ Editorial · July 6, 2026
Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →
This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper presents an interesting and mechanistically plausible targeted cancer therapy candidate, with adequate cell-based and animal-model evidence supporting selective killing of cancer cells via ROS stress-response targeting. However, the study suffers from insufficiently reported experimental design details (randomization, blinding, power analysis), incomplete identification of key resources (antibody catalog numbers, cell line authentication), and absent data availability — all limiting the ability to independently assess internal validity and reproducibility.
Three independent evaluators assessed all eight dimensions; there was disagreement on study design (pass vs warn vs fail), key resources (pass vs warn vs fail), and reporting transparency (warn vs pass). The synthesis weighed the more specific, evidence-rich critiques from reviewers 2 and 3. The statistics verification could not recompute any test because all reported p-values were threshold-only (e.g., p<0.0001) without test statistics — the paper's statistical reporting is imprecise but not demonstrably erroneous.
12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
3 integrity concerns flagged (0 high).
13 copyedit issues flagged (1 major): mostly consistency, other, typo.
Checked 28 references: 27 verified — 1 unresolved.
2 data/code links checked; 2 live.
POST-PUBLICATION AUDIT: The published findings should be interpreted with caution. The missing IACUC statement, lack of randomization/blinding details for animal experiments, and absence of effect sizes reduce confidence in the quantitative conclusions. An informed reader should weigh that the headline claim 'PL is more effective than paclitaxel' in the MMTV-PyVT model is not statistically supported in the paper (no direct statistical comparison is reported). An erratum or independent re-analysis would be warranted for the statistical and resource reporting gaps.